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AIDS 2014, 28:1075–1080Massive hypereosinophilia and vasculitis associated with major expansion of interleukin-5-producing CD8R
T cells in HIV-1 infectionWe report here on a distinct form of systemic necrotizing
vasculitis with extensive digital gangrene during HIV-1
infection accompanied by massive eosinophilia, and
major expansion of interleukin (IL)-5-producing per-
ipheral blood CD8þ T cells with CD8þ T-cell infiltration
in the skin biopsy, strongly suggesting that CD8þ T-cell
dysregulation was involved in its pathogenesis.
A 51-year-old HIV-1-seropositive Caucasian man pre-
sented with a 3-day progressive necrosis of fingers and
toes (Fig. 1a), and discrete ulcerated lesions on the face
and hands, with marked eosinophilia (6830/ml), high
erythrocyte sedimentation rate (80mm), and C-reactive
protein (15.6mg/dl), as well as lymphopenia (450/ml)
with severe CD4þ T-cell depletion (9 cells/ml; 1.7%) and
viremia of 75 000 RNA copies/ml. HIV-1 infection was
diagnosed 11 years before (96 CD4þ T cells/ml; 421
HIV-1 RNA copies/ml), and intermittently treated,
being asymptomatic during the past 4 years without
antiretroviral therapy (ART) due to patient decision. Skin
biopsies of the digit lesions revealed thrombi in the
dermal vessels with necrosis of the epidermis and
perivascular lymphocytic infiltration (CD8þ) involving
superficial and profound layers (Fig. 1b). There were IgM
and complement in the superficial vessels, but no
leucocytoclasia, IgA deposits, cytomegalovirus (PCR)
or HIV (p24, immunohistochemistry) were detected.
There was neither angiographic alteration of major
arterial vessels nor cryoglobulinemia. Anti-neutrophil
cytoplasmic autoantibodies and other autoantibodies
were negative. Myelogram and bone biopsy showed a
slight increase in eosinophil number, without morpho-
logical abnormalities. Other concomitant active infec-
tions were excluded, including HCV, as well as other
possible causes of hypereosinophilia, including drug
hypersensitivity, and intestinal and systemic parasitosis.
Eosinophilia is not rare in HIV-1 infection, but it is
usually mild to moderate and not associated with tissue
damage. Massive eosinophilia similar to the one observed
in this case is a recognized feature of ‘idiopathic’
hypereosinophilic syndrome, where tissue damage occurs
in association with the eosinophilia [1]. In the
lymphocytic variant, there is typically an abnormal
expansion of T cells producing IL-5, an important
eosinophil growth factor that may underlie the eosino-
philia, with identification of T-cell clones with several
possible phenotypes, namely CD3CD4þ, CD3þCD4
CD8 and CD4þCD7 [1]. We identified an abnormalCopyright © Lippincott Williams & Wilkins. Unaut
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(38% of the CD8þ T cells) in our patient, which did
not concomitantly produce IL-4 (Fig. 1c), assessed as
previously described [2]. Importantly, the proportion of
CD8þ T cells producing interferon (IFN)-g (10% of
CD8þ T cells) was much below the expected levels
for this disease stage, despite the documented expansion
of memory-effector CD8þ T cells (83.1% of the
CD8þ T cells), with an activated phenotype (32.2%
CD38þHLA-DRþwithin CD8þT cells) [2,3]. Hence, it
is reasonable to speculate that, in the context of an
atypically low frequency of interferon-g-producing cells
[2,3], HIV may drive T-cell differentiation towards an
IL5-producing CD8þ T-cell phenotype.
HIV-associated vasculitis can affect all types of blood
vessels and covers the entire spectrum of vasculitis as
described for non-HIV patients, with multifactorial
pathogenic mechanisms having been proposed, including
immune dysregulation caused by CD8þ T-cell expansion
[4,5]. Our patient had some clinical features similar to
those of HIV-associated polyarteritis nodosa-like vascu-
litis, although the CD8þ perivascular infiltration and the
massive eosinophilia with expansion of IL-5-producing
CD8þ T cells did not fit this diagnosis [4,5]. A case of
HIV infection with marked eosinophilia and digital
gangrene has previously been reported by Enelow et al.
[6], but no immunologic investigation of IL-5-producing
T cells or the phenotype of cells involved in the
perivascular infiltrate was performed.
The percentage of IL-5-producing CD8þ T cells and the
eosinophil count rapidly decreased after introduction of
ART (tenofovir/emtricitabine and lopinavir/ritonavir,
based on phenotypic and genotypic tests), corticosteroids
(prednisolone 1mg/kg/day, 6 weeks), and plasmapheresis
(15 sessions). This was accompanied by a clear improve-
ment of the ischemic symptoms, although amputation of
the necrotic phalanges was required. One year after
stopping steroid therapy, the abnormal T-cell population
was absent, and the eosinophil count remained at normal
levels, with an effective control of viremia under ART,
despite the poor CD4þ T-cell recovery (<200 cells/ml).
In conclusion, we documented a new form of vasculitis in
HIV infection that is associated with IL-5-producing
CD8þ T cells and clinically characterized by digital
gangrene and eosinophilia. Corticosteroid therapy and
plasmapheresis in conjunction with ART corrected thehorized reproduction of this article is prohibited.
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Fig. 1. Severe vasculitis associated with an expansion of
interleukin (IL)-5-producing CD8R T cells in an HIV-1-
infected patient. (a) Edema of the digits with necrosis of
the first phalanx and intense cyanosis of the second phalanx
of the third and fifth fingers of the right hand and second and
fifth fingers of the left hand; discrete ulcerated lesions in the
back of the hands. (b) Skin biopsy showing a vasculitic lesion
with a perivascular infiltration of CD8þ lymphocytes revealed
by immunohistochemistry stain (400). (c) Cytokine pro-
duction by CD8þ T cells before and after treatment. Freshly
isolated peripheral blood mononuclear cells were stimulated
for 4 h with phorbol 12-myristate 13-acetate/ionomycin in the
presence of Brefeldin A. Dot plots show the proportion of cells
producing both IL-5 and IL-4, or either of the two, within the
CD8þ T-cell population before initiation, and after 20 days of
treatment.abnormal CD8þ population and the eosinophilia,
concomitantly with clinical improvement. Our case
justifies the increase of clinicians’ awareness to this form
of HIV-associated systemic vasculitis and emphasizes a
role for CD8þT cells in the tissue lesions in the context of
vasculitis-eosinophilic syndromes.Acknowledgements
We thank Cristina Alexandra Pignatelli for collaboration
in the immunohistochemistry study.
Author contributions: Clinical data collection: I.J., B.A.,
J.M.S., and R.M.M.V.; performed research: I.J., L.S.A.,
R.B.F., and RT; designed the study, analyzed data and
wrote the paper: I.J., A.E.S., and R.M.M.V.
Conflicts of interest
Funding: This work was supported by ‘Fundac¸a˜o para a
Cieˆncia e a Tecnologia’ (FCT) and by ‘Programa
Operacional Cieˆncia e Inovac¸a˜o 2010’ [POCI2010]
[PIC/IC/82712/2007 to AES], as well as by Fundac¸a˜o
Calouste Gulbenkian to AES. RBF and RT received
scholarships from FCT.
There are no conflicts of interest.
Ineˆs Jorgea, Beatriz Amarala, Luis M.S.R. Soares-
Almeidab,c, Russell B. Foxalld, Rita Tendeirod, Joa˜o M.
Santosa, Ana E. Sousad and Rui M.M. Victorinoa,d,
aClı´nica Universita´ria de Medicina 2, bClı´nica Uni-
versita´ria de Dermatologia, Hospital de Santa Maria,
CHLN, cUnidade de Investigac¸a˜o em Dermatologia,
and dUnidade de Imunologia Clı´nica, Instituto de
Medicina Molecular, Faculdade de Medicina, Univer-
sidade de Lisboa, Portugal.
Correspondence to Professor Rui M.M. Victorino,
Clinica Universita´ria de Medicina 2, Faculdade de
Medicina da Universidade de Lisboa, Av. Prof Egas
Moniz, 1649-028 Lisboa, Portugal.
Tel: +351 217985169; fax: +351 217999527;
e-mail: rvict@fm.ul.pt
Received: 18 December 2013; revised: 6 January
2014; accepted: 6 January 2014.References
1. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ,
Wechsler ME, et al. Refining the definition of hypereosinophilic
syndrome. J Allergy Clin Immunol 2010; 126:45–49.
2. Sousa AE, Chaves AF, Loureiro A, Victorino RM. Comparison
of the frequency of interleukin (IL)-2-, interferon-gamma-, and
IL-4-producing T cells in 2 diseases, human immunodeficiency
virus types 1 and 2, with distinct clinical outcomes. J Infect Dis
2001; 184:552–559.rized reproduction of this article is prohibited.
Correspondence 10773. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z,
Victorino RM. CD4 T cell depletion is linked directly to immune
activation in the pathogenesis of HIV-1 and HIV-2 but only
indirectly to the viral load. J Immunol 2002; 169:3400–3406.
4. Patel N, Khan T, Espinoza LR.HIV infection and clinical spectrum
ofassociatedvasculitides.CurrRheumatolRep2011;13:506–512.
5. Guillevin L. Vasculitides in the context of HIV infection. AIDS
2008; 22 (Suppl 3):S27–33.Copyright © Lippincott Williams & Wilkins. Unaut6. Enelow RS, Hussein M, Grant K, Cupps TR, Druckman D,
Mortazavi A, et al. Vasculitis with eosinophilia and digital gang-
rene in a patient with acquired immunodeficiency syndrome.
J Rheumatol 1992; 19:1813–1816.DOI:10.1097/QAD.0000000000000205Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and
review of the literatureRaltegravir (RAL) is the first integrase strand transfer
inhibitor against HIV [1] and it is placed within first-line
options in the treatment of HIV infection [2]. It is also
the first agent of a new class of antivirals, which now
includes two additional drugs [2], namely elvitegravir
and dolutegravir.
Many pharmacological agents, including antiretrovirals
[3–5], may cause a drug reaction with eosinophilia and
systemic symptoms (DRESS) syndrome, a potentially
life-threatening drug hypersensitivity reaction, which
characteristically arises after a long latency period. Due to
the broad spectrum of clinical features, it may be a great
mimicker of other diseases [5]. Clinical symptoms include
fever, rash, lymphadenopathy, hematological abnormal-
ities (most often eosinophilia), and involvement of at least
one internal organ system (especially the liver, but also the
kidneys, lungs, and heart). The mortality rate has been
estimated at 10%, mostly due to liver failure [5].
Drug reaction with eosinophilia and systemic symptoms
syndrome associated with RAL exposure has been rarely
reported in HIV-1-infected patients [6–8]. We report a
case of DRESS syndrome associated with RAL use in an
African immigrant and review the literature on this topic.
A 39-year-old man from Ivory Coast was admitted to
hospital in January 2013 for low-grade fever, weight loss
and abdominal pain. He tested positive for HIV and his
CD4þ T-lymphocyte count was 3 cells/ml, HIV RNA
was 4.5 106 copies/ml, whereas urinalysis showed a
heavy proteinuria (3 g/day), interpreted as HIV-associ-
ated nephropathy. He was empirically treated for atypical
mycobacteriosis with ethambutol, azytromycin, and
rifabutin (blood cultures yielded Mycobacterium avium
few weeks later) for a total of 6 months, and he was put on
highly active antiretroviral therapy (HAART) (zidovu-
dine/lamivudine þ darunavir/ritonavir), along with
cotrimoxazole prophylaxis. His viral load decreased
to less than 50 copies/ml and CD4þ cell count was
30 cells/ml at week 24 after HAART initiation.
In July 2013, he developed a symptomatic muscular
toxicity (creatine phosphokinase increased to 5000UI/l,
n.v.<186UI/l) and zidovudine/lamivudine was replaced
by RAL, in the hypothesis of zidovudine-inducedmyopathy, whereas, for concomitant neutropenia, cotri-
moxazole was switched to atovaquone.
After 4 weeks since RAL introduction, the patient
developed fever with an itchy rash on the limbs and
scalp, and painful oral aphthae. Hewas admitted to hospital
in August 2013 and his blood tests showed an icteric
cholestatic hepatitis and a low-grade anemia: hemo-
globin (Hb)¼ 11.7mg/dl, white blood cell count¼
6200 cells/ml, with atypical lymphocytes and eosinophilia
(560 cells/ml), aspartate aminotransferase (AST) 354 IU/l,
alanine aminotransferase (ALT) 497 IU/l, total bilirubin
3.9mg/dl, alkaline phosphatase 480 (n.v. <140). Blood
smear and antigen for malaria were negative.
In the following days, the patient developed a high-grade
fever (up to 398C), associated with a sharp increase in
inflammatory markers (C-reactive protein¼ 10.5mg/dl,
ferritin>8000 ng/ml – n.v. 250), and increased jaundice:
total bilirubin rose up to 27mg/dl, with direct bilirubin
25mg/dl, AST 940, ALT 617U/l, gamma-glutamyl-
transferase (GGT) 788U/l (n.v. <50) and lactate
dehydrogenase 2655U/l (n.v. <460). Eosinophilia
increased to 1320 cells. Chest radiograph was unremark-
able and blood cultures for bacteria, fungi and myco-
bacteria were negative. He tested negative for hepatitis B
virus and hepatitis C virus,whereas the liver biopsy showed
an inflammatory infiltration, but was inconclusive.
Schistocytes were absent and renal function remained
normal. He also developed a severe anemia (Hb decreased
to 7.4 g/dl, with normal platelet count) with a hemolytic
pattern (aptoglobin fell from 127 to <5mg/dl, direct
Coombs test was positive for IgG and C3b/d at high titer),
which was attributed to intravenous piperacillin/tazobac-
tam, which the patient was receiving for a provisional
diagnosis of bacterial cholecystitis (ultrasonography of the
abdomen showed thickening of gall bladder wall).
In suspicion of a drug reaction, he was treated with oral
prednisone (0.5mg/kg daily) for 5 days, with a rapid
improvement and a sudden relapse of symptoms at with-
drawal.
He was restarted on prednisone (1mg/kg daily),
with prompt resolution of symptoms and a gradual
improvement of the biochemical abnormalities. He washorized reproduction of this article is prohibited.
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Table 1. Characteristics of patients with RAL-associated DRESS syndrome.
Patients
1 (current) 2 (ref. [6]) 3 (ref. [7]) 4 (ref. [8])
Age (years) 39 55 46 64
Ethnic group African (Ivory Coast) African (UK) African (Congo) African (Texas)
Sex Male Female Female Female






CD4þ cell count (cells/ml) 30 305 412 522
Time since starting RAL (weeks) 4 4 8 6
Fever Yes Yes Yes No
Cutaneous rash Yes Yes Yes Yes
Facial edema No No No Yes
Leucocytosis No Yes No Yes
Eosinophilia Yes Yes No Yes
Lymphadenopathy No No Yes Yes
Increased AST/ALT Yes Yes Yes Yes
Agents associated with RAL DRV/r ATV/r TDF þ LPV/r DRV/r
Hospitalization Yes Yes Yes Yes
Steroid treatment Yes Yes No Yes
Outcome Resolved Resolved Resolved Resolved
DRESS, drug reaction with eosinophilia and systemic symptoms; RAL, raltegravir.discharged home after 2weeks, in good clinical conditions.
The prednisone was tapered over 8 weeks, without
recurrence of symptoms. The patient was switched to
darunavir/ritonavir and abacavir/lamivudine, and, at
the last follow-up visit in November 2013, he was
healthy, with HIV RNA 184 copies/ml, CD4þ cell
count 92 cells/ml, Hb 14.6 g/dl, AST 89U/l, ALT
111U/l and GGT 679U/l.
Raltegravir is likely to expand its use over the next years,
both in therapy [2] and postexposure prophylaxis [9], due
to its antiviral efficacy, good tolerability, low toxicity
profile, and low potential for drug-to-drug interactions
[1]. Recently, RAL has also been proposed in second-line
options in resource-poor settings, after failing first-line
non-nucleoside reverse-transcriptase inhibitor-based
regimens [10].
According to a proposed scoring system for DRESS
syndrome, our case scored higher than 5, confirming the
diagnosis [11]. The DRESS syndrome linked to RAL has
been so far described in three patients only, all of African
origin, whose clinical features are summarized in Table 1
[6–8]. It is an idiosyncratic reaction to a drug and it is
likely dependent on genetic factors [3]. No significant
differences in any RAL pharmacokinetic parameters
between African-American and white individuals have
been reported [12].
The severe anemia developed in our patient was
reasonably caused by piperacillin, because massive
hemolysis after administration of this antibiotic has been
reported in literature [13] and hemolytic anemia has not
been described in DRESS syndrome [5].
In case of DRESS syndrome, RAL discontinuation is
mandatory, symptoms may require longer than 2 weeks topyright © Lippincott Williams & Wilkins. Unauthorecover and oral steroids remain commonly prescribed for
several weeks, although optimum treatment is unclear [5].
Clinicians should be aware of this uncommon, but
potentially fatal, adverse event associated with RAL use,
particularly in African patients with advanced HIV
infection, where polyfarmacy, bacterial sepsis, mycobac-
terial disease and immune reconstitution syndrome may
be significant confounders.Acknowledgements
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DOI:10.1097/QAD.0000000000000204Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patientMaraviroc is the first CCR5 receptor antagonist for the
treatment of HIV-infected patients and was approved for
use in the USA in April 2007. Hepatoxocity has been
reported within 1 month of starting maraviroc in a small
proportion of patients, and caution has been advised
when administering maraviroc to patients with pre-
existing liver dysfunction or who are coinfected with
either hepatitis B virus (HBV) or hepatitis C virus (HCV).
However, there have been no reports of reactivation of
HBV in patients treated with maraviroc.
We saw a 67-year-old man coinfected with HIVand HBV
who had originally initiated antiretroviral therapy in
1994. His current regimen when presenting to our
institution included tenofovir/emtricitabine, darunavir,
tipranavir, ritonavir and raltegravir. His CD4þ cell count
was 219 cells/ml, HIV-1 RNA level 56 820 copies/ml,
HBV DNA level undetectable, and hepatic transaminases
were normal [AST (aspartate aminotransferase) 18 IU/l,
alanine aminotransferase (ALT) 16 IU/l]. HIV genotypic
resistance testing revealed pan-nucleoside/tide reverse
transcriptase inhibitor resistance, as well as efavirenz,
nevirapine and raltegravir resistance. A coreceptor
tropism assay indicated a CCR5-tropic virus. His
therapeutic regimen was adjusted to include tenofovir/
emtricitabine for his chronic HBV infection, and
ritonavir, darunavir, etravirine, and maraviroc at a
reduced dose of 150mg twice daily for his HIV.
Eight months after initiation of his new regimen, his
CD4þ cell count had risen to 287 cells/ml and HIVRNA
level had fallen to 20 copies/ml. However, the patient’s
tranaminases had risen almost ten-fold (AST 140 IU/l,
ALT 166 IU/l). HBV DNA level was elevated at
5 751 900 copies/ml. There had been no reported lapsein the patient’s tenofovir/emtricitabine therapy. HBV
resistance testing revealed L180M and M204V mutations
predicting lamivudine resistance but not tenofovir
resistance. Maraviroc was discontinued and atazanvir
was added to his regimen. Over the course of the next 10
months, the patient’s elevated transaminases returned to
normal and his HBV DNA level once again became
undetectable without the addition of a second anti-
HBV agent.
In the MOTIVATE 1 and 2 trials, the incidence of grade
3 and 4 elevations in AST and ALT associated with
maraviroc ranged from 3% to 4%, which was not
significantly different from that found in the placebo
group [1]. Only 5% of the participants in the
MOTIVATE 1 trial and 7% of those in the MOTIVATE
2 trial were coinfected with hepatitis B and 8% of
coinfected patients experienced a grade 2 or greater
increase in ALT level [2]. There were no reports of
hepatitis B reactivation in this population. Nevertheless,
the prescribing information for maraviroc includes a
warning that prescribers should use caution when
administering maraviroc to patients who are coinfected
with hepatitis B.
Maraviroc-induced HBV reactivation is theoretically
possible since blockade of CCR5 receptors could
diminish cell-mediated immune responses against HBV.
CC ligand 3 (CCL3), CCL4 and CCL5 are three
important chemokines that activate natural killer cells,
macrophages and T lymphocytes through the CCR5
receptor and are required for recruitment of activated
immune cells to the HBV-infected liver [3]. CCR5
receptors have also been shown to be up-regulated in
HBV-specific CD8þ cells from patients with chronichorized reproduction of this article is prohibited.
Co
1080 AIDS 2014, Vol 28 No 7hepatitis B with low levels of viremia, again suggesting
that the CCR5 receptor is important in maintaining viral
suppression [4].
Although an alternative explanation for the HBV
reactivation could be lack of effective antiviral therapy,
this is not likely in our opinion. The patient did not report
any interruption in his therapeutic regimen, which is
supported by the observed improvement in his HIV
RNA. Furthermore, simply removing maraviroc from his
regimen appears to have effectively inhibited HBV
replication again. There is an ongoing study evaluating
hepatic transaminase elevations in patients coinfected
with HIV and either HBV and/or HCV who are
receiving maraviroc [5], and changes in plasma HBV
DNA levels are being monitored as a secondary outcome
measure. However, this study is not estimated to be
completed until mid 2015 but, hopefully, the results will
shed more light on this possible association between
maraviroc use and HBV reactivation.Acknowledgements
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